Cardiff Oncology Q2 2026 Earnings Report

Cardiff Oncology EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.17
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cardiff Oncology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.06 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cardiff Oncology Announcement Details

• Quarter: Q2 2026
• Date: 8/4/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Cardiff Oncology (NASDAQ:CRDF) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development. These candidates target pathways implicated in tumor immune evasion, with the goal of inducing immunogenic cell death and improving response rates. The company’s strategic approach emphasizes combination regimens, pairing its agents with established immunotherapies to potentially increase efficacy in solid tumors.

Since its founding in 2015, Cardiff Oncology has pursued strategic collaborations to accelerate its programs, notably entering a research agreement with Merck & Co. to explore combination studies with pembrolizumab. The company conducts its clinical trials across multiple sites in the United States and internationally, serving a global oncology community committed to developing new therapeutic options for patients with cancer.